Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
GfV 2024
Programm
Poster
Personen
Suche
DE
Zurück
Poster Session
Poster exhibition
Antiviral therapy and resistance
Termin
Datum:
25.03.2024
Zeit:
13:00
–
21:00
Ort / Stream:
Antiviral therapy and resistance
Programm
Poster
P 065
Nanobody-engineered nuclear E3-ubiquitin ligase adaptor effectively degrades PRRS Virus RdRp through lysosomal pathway in cytoplasm
Professor Fandan Meng (Harbin / CN)
Antiviral therapy and resistance
Poster
P 066
In vitro profiling of the antiviral peptide TAT-I24
Dr. Hanna Harant (Vienna / AT)
Antiviral therapy and resistance
Poster
P 067
An RNA replicon system to investigate promising inhibitors of feline coronavirus
Kimberly Schmied (Bern / CH)
Antiviral therapy and resistance
Poster
P 068
Zapnometinib – A host targeted MEK1/2-inhibitor with broad anti-SARS-CoV-2 activity, strong synergism with licensed drugs and a high barrier towards emergence of resistance
Dr. André Schreiber (Münster / DE)
Antiviral therapy and resistance
Poster
P 069
The role of gut bacteria mediated metabolites in anti-viral immune responses
Magdalena Siller (Vienna / AT)
Antiviral therapy and resistance
Poster
P 070
Antiviral activity of small molecules against coronaviruses
Natalie M. Köhler (Hannover / DE)
Antiviral therapy and resistance
Poster
P 071
Small molecule antiviral for Dengue Virus selectively inhibits the ER co-translational translocation of the flaviviral polyprotein
Dr. Marijke Verhaegen (Leuven / BE)
Antiviral therapy and resistance
Poster
P 072
Chimeric antigen receptor T cells to fight cytomegalovirus infections
Sabrina Kübel (Erlangen / DE)
Antiviral therapy and resistance
Poster
P 073
Mechanisms of antiviral action of the influenza defective interfering particle "OP7"
Dr. Julita Piasecka (Magdeburg / DE)
Antiviral therapy and resistance
Poster
P 074
Nucleoside analogues and inhibitors of pyrimidine synthesis synergize to suppress Influenza A virus replication
Leon Schrell (Göttingen / DE)
Antiviral therapy and resistance
Poster
P 075
The herpesviral DNA-polymerase associated factor as a putative drug target
Marie-Sophie Schulze (Hannover / DE)
Antiviral therapy and resistance
Poster
P 076
Novel targeting strategies of the cytomegalovirus nuclear egress complex based on covalently binding warhead compounds
Julia Tillmanns (Erlangen / DE)
Antiviral therapy and resistance
Poster
P 078
Preclinical development of host-directed dual-target small molecule inhibitors as broad-spectrum antivirals
Dr. Alexandra Herrmann (Gräfelfing / DE)
Antiviral therapy and resistance
Poster
P 079
The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage
Dr. Ronghui Liang (Hong Kong / HK)
Antiviral therapy and resistance
Poster
P 080
Defective interfering particles of influenza A virus as broad-spectrum antivirals
Dr. Sascha Young Kupke (Magdeburg / DE)
Antiviral therapy and resistance
Poster
P 081
Enhancing VIRIP-Derived HIV-1 gp41 fusion peptide inhibitors through advanced atomistic modeling
Dr. Christoph Jung (Eggenstein-Leopoldshafen / DE)
Antiviral therapy and resistance
Poster
P 082
Ophthalmic Co-Culture meets
in vitro
3D-Models in virology research
Marco Bechtel (Frankfurt am Main / DE)
Antiviral therapy and resistance
Poster
P 083
Differential sensitivity of SARS-CoV-2 virus variants to the antiviral peptide TAT-I24
Eva Kicker (Graz / AT)
Antiviral therapy and resistance
Poster
P 084
Discovery and characterization of Trypstatin as inhibitor of TMPRSS2 and respiratory viral infection
Jan Lawrenz (Ulm / DE)
Antiviral therapy and resistance
Poster
P 085
Development of human pan-hantavirus antibodies for treatment of hantavirus-associated diseases
Dr. Nooran Elleboudy (Berlin / DE)
Antiviral therapy and resistance
Poster
P 086
Discovery of novel autophagy inducing anti-viral peptides derived from the human peptidome
Dennis Freisem (Ulm / DE)
Antiviral therapy and resistance
Poster
P 087
CRISPR Cas13 as an antiviral tool against respiratory RNA viruses
Anna Carolina Henkel (Hannover / DE)
Antiviral therapy and resistance
Poster
P 088
PROTAC-mediated targeted protein degradation of the SARS-CoV-2 main protease using an allosteric warhead
Christopher Veeck (Marburg / DE)
Antiviral therapy and resistance
Poster
P 089
Host cell factors as antiviral targets to limit adenovirus infection
Dr. Sebastian Schloer (Hamburg / DE)
Antiviral therapy and resistance
Poster
P 090
Influence of AAV capsid tropism on transcriptional activity of the delivered vector construct
Jannik T. Wagner (Erlangen / DE)
Antiviral therapy and resistance
Poster
P 091
A comprehensive study of SARS-CoV-2 main protease (M
pro
) inhibitor-resistant mutants selected in a VSV-based system
Francesco Costacurta (Innsbruck / AT)
Antiviral therapy and resistance
Poster
P 092
Optimization of mRNA encapsulated Lipid nanoparticles (LNPs) for
in vivo
administration of monoclonal antibodies
Hanife Dinc (Erlangen / DE)
Antiviral therapy and resistance
Poster
P 093
Inhibition and specific targeting of infected cells by VSV particles carrying viral receptors
Dr. Fabian Zech (Ulm / DE)
Antiviral therapy and resistance
Poster
P 094
Thioxothiazolo[3,4-a]quinazoline derivatives inhibit the human cytomegalovirus alkaline nuclease
Andrea Salvatore Albanese (Hamburg / DE)
Antiviral therapy and resistance
Poster
P 095
Pan-serotype dengue virus inhibitor JNJ-A07 targets the NS4A-2K-NS4B interaction with NS2B/NS3 and blocks
de novo
formation of replication organelles
Dr. Dominik Kiemel (Heidelberg / DE)
Antiviral therapy and resistance
Poster
P 096
In vitro
and
in vivo
effects of
Pelargonium sidoides DC.
root extract EPs
®
7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2
Jackson Emanuel (Berlin / DE)
Antiviral therapy and resistance
Poster
P 097
Multimerization of mAbs and their Fab derivatives by functionalizing DNA-Origami Nanoshells improves Influenza A H1N1 Neutralization in vitro
Michael Schachtner (Regensburg / DE)
Antiviral therapy and resistance
Poster
P 098
Design of peptides inhibiting SAMHD1 activity
Aleksandra Mitric (Erlangen / DE)
Antiviral therapy and resistance
Poster
P 099
Exploring HIV-1 splice site susceptibility to splicing inhibitors as a potential therapeutic strategy to interfere with viral replication
Laura Peter (Düsseldorf / DE)
Antiviral therapy and resistance
Poster
P 100
Deciphering the persistence of bornaviruses
Sebastian Giese (Freiburg / DE)
Antiviral therapy and resistance
Poster
P 101
Geno2pheno: De Novo Recombination detection of A6 subtypes
Dr. Martin Pirkl (Cologne / DE)
Antiviral therapy and resistance
Poster
P 102
Design of dual chimeric virus to test cross-resistance to or synergy of coronavirus inhibitors
Dr. Emmanuel Heilmann (Innsbruck / AT)
Antiviral therapy and resistance
Poster
P 103
The kidney as extrahepatic site of Hepatitis E Virus replication
Dr. André Gömer (Bochum / DE)
Antiviral therapy and resistance
Poster
P 104
Development of Sudan ebolavirus VP40 inhibitors via structure-guided drug design
Dr. Anke-Dorothee Werner (Marburg / DE)
Antiviral therapy and resistance
Poster
P 105
Limited high-throughput screening compatibility of the phenuivirus cap-binding domain
Janna Scherf (Hamburg / DE)
Antiviral therapy and resistance
Poster
P 106
The BRD4- selective small molecule ZL0580 interferes with protein expression of transcription elongation factor ELL2 and HTLV-1
Tax
Abarna Baheerathan (Erlangen / DE)
Antiviral therapy and resistance
Poster
P 107
Novel small-molecule inhibitors targeting the entry of the respiratory syncytial virus
Leila Issmail (Leipzig / DE)
Antiviral therapy and resistance
Poster
P 108
Preclinical studies revealed the high efficacy of immunotherapy by equine polyclonal antibodies against novel SARS-CoV-2 variants of concern
Dr. Maksym Kitsera (Hamburg / DE)
Antiviral therapy and resistance
Poster
P 109
Fate of Spike expressed from genetic vaccines and produced during SARS-CoV-2 infection: A unifying pathogenetic link to some pathologies following vaccination or observed in COVID-19?
Dr. Lea Krutzke (Ulm / DE)
Antiviral therapy and resistance
Poster
P 110
Cyclosporin A inhibits VSV infection by Interferon-λ mediated induction of CMPK2
Lars Meier (Marburg / DE)
Antiviral therapy and resistance
Poster
P 111
Characterizing HCMV pUL77 as potential druggable target
Jan Marc Beneke (Lübeck / DE)
Antiviral therapy and resistance
Poster
P 112
Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs
Dr. Raphael Jami (Tuebingen / DE)
Antiviral therapy and resistance
Poster
P 113
Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies
Pascal von Maltitz (Ulm / DE)
Antiviral therapy and resistance
Poster
P 114
ATO (
Arsenic Trioxide
) impacts hepatitis B virus core nuclear localization and efficiently interferes with HBV infection
Professor Sabrina Schreiner (Freiburg / DE)
Antiviral therapy and resistance
Poster
P 115
Synergistic interference with SARS-CoV-2 replication by Monupiravir-derived N4 hydroxycytidine and inhibitors of CTP synthetase
Antje Dickmanns (Göttingen / DE)
Antiviral therapy and resistance
Poster
P 116
Analysis of Fab fragments from neutralizing antibodies for prevention of cell-associated spread of human cytomegalovirus
Kerstin Laib Sampaio (Ulm / DE)
Antiviral therapy and resistance
Poster
P 117
Elevating antiviral testing standards through advanced multi-organ-chips
Dr. Susann Kummer (Berlin / DE)
Antiviral therapy and resistance
Poster
P 118
Highly specific SARS-CoV-2 main protease (M
pro
) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system
Stefanie Rauch (Innsbruck / AT)
Antiviral therapy and resistance
Poster
P 119
The antiviral effect of
Anagallis arvensis
L. saponins on HSV-1 correlates with their fusion-inhibitory activity
Nica Classen (Muenster / DE)
Antiviral therapy and resistance
v1.19.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz